Verley Raises $37.7M to Expand in the U.S.
French nutrition company Verley has secured $37.7 million in an oversubscribed Series A round, led by Alven, with participation from Blast, Bpifrance, and existing investors Sofinnova and Sparkfood.
The funding will support business model optimization, customer expansion, product portfolio growth, and international commercialization, with a primary focus on the U.S. market following key regulatory clearance from the U.S. Food and Drug Administration (FDA).
A New Era for Protein Production
Verley produces high-performance whey proteins, specifically beta-lactoglobulin, through precision fermentation — enabling dairy protein production without animals.
The company reports:
- 97% reduction in greenhouse gas emissions
- 99% reduction in water consumption
With global whey supply facing shortages and volatility, Verley positions itself as a stable and sustainable alternative protein supplier.
Strategic Capital to Accelerate U.S. Entry
Proceeds will fund:
- U.S. commercial launch
- Initial customer scale-up
- Hybrid manufacturing capacity expansion
- Continued R&D investment
The company recently received a “No Questions Letter” from the FDA confirming its functionalized whey protein is GRAS, significantly de-risking commercialization.
Total funding raised now exceeds $60 million since inception.
B2B Strategy and Global Ambitions
Operating under a B2B model, Verley markets its ingredients under the FermWhey brand, engineered for superior solubility, stability, and purity across demanding applications.
Commercial launch in the U.S. is expected by end of 2026, with regulatory efforts underway in Europe and strategic expansion plans targeting the Middle East.
